In the clinical treatment of diabetic foot, HUC-MSCs could be targeted to the ulcer and increase the formation of vascular endothelial growth factor (VEGF) and brain-derived neurotrophic factor (BDNF). This evidence concerns the gene VEGFA and ulcer disease.